Featuring perspectives from Dr Matthew Gubens, including the following topics:
- Investigator perspectives on emerging findings with immunotherapy for resectable non-small cell lung cancer (NSCLC) (0:00)
- Immunotherapy for early-stage unresectable disease (7:51)
- First-line therapy for patients with metastatic NSCLC with and without targetable mutations (17:46)
- Current and potential roles of antibody-drug conjugates in the treatment of NSCLC (21:55)
- Emerging biomarkers in small cell lung cancer research (26:45)
CME information and select publications